PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

EMA accepts application for leukaemia drug from Otsuka and Astex

The European Medicines Agency (EMA) has accepted Otsuka Pharmaceutical and Astex Pharmaceuticals’ marketing authorisation application (MAA) for an oral fixed-dose combination of decitabine and cedazuridine (ASTX727) for the initial treatment of adults with acute myeloid leukaemia (AML) who are not candidates for standard induction chemotherapy.

The application is supported by positive results from the phase 3 ASCERTAIN clinical trial which demonstrated an exposure equivalence of an oral fixed-dose of decitabine and cedazuridine to a standard 5-day regimen of intravenous (IV) decitabine – the current standard of care for AML – using a two-cycle cross-over study design.

Safety findings for the fixed-dose combination of decitabine and cedazuridine were ‘generally consistent’ with those anticipated for IV decitabine, Otsuka reported.

AML is the most common form of acute leukaemia in adults, with a median age at diagnosis of approximately 70 years. In Europe, the incidence of AML is increasing, rising from 3.48 in 1976 to 5.06 patients per 100,000 population in 2013.

The outlook for patients diagnosed with AML has improved over time due to improved care and treatment, but between 2000 and 2007, five-year survival for patients was just 17%, Otsuka reported.

If approved, oral decitabine and cedazuridine would be the first and only oral hypomethylating agents licensed in the European Economic Area (EEA) for the initial treatment of adults with AML who are ineligible for intensive chemotherapy, offering a potentially more convenient treatment regimen.

Oral decitabine and cedazuridine fixed-dose combinations are approved in the US and Canada under the brand name Inqovi for the treatment of adult patients with intermediate and high-risk myelodysplastic syndromes (MDS), including chronic myelomonocytic leukaemia (CMML).

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026